Ann: Half Yearly Report and Accounts, page-2

this is the key passage of this night's communiqué.

Commitments At June 30, 2018, the Company had commitments on the basis of contracts for the production of trofinetide equal to approximately Euro 1.9 million and commitments under contracts for non-clinical toxicology studies of approximately USD 0.6 million. In July 2018, the Company made an additional commitment of € 2.25 million under a contract for the production of trofinetide. The commitments should become payable during the period up to March 2019.

therefore Trofinetide is produced in Europe and not in America and even more has more than doubled the production compared to the starting intentions so there is middle of the phase 3 study also for FX. going even further with imagination, at this point it may be that the delays to open phase 3 by Acadia are linked to the fact that two studies are opened simultaneously and not just one for Rett. it means in terms of profit for the company, other money coming immediately and many others respect Rett for further royalties. not only that, the possibility is increased for the granting of the vaucher by the FDA for rare pediatric diseases that is worth more than 400 million dollars. it is quite evident therefore that behind Acadia there is someone much bigger and who has an interest in making money with the whole package of Trofinetide.
Having said this, on the market the downward game managed by logarithms is now over; yesterday and today there were more sales intentions than buying but with rising price. it means that those who have put up higher-priced packages of shares and immediately been absorbed are the inverse of the last few weeks when stocks were sold and there were no substance buyers at ten percentage points down. I would say that the suspension of the Landstead agreement and therefore the reacquired possibility to stop the market at any moment to discourage the down speculators who fear to sell shares and not be able to resume them if not at much higher prices as a consequence of a reopening of the market with a different scenario of events. who collects on the market now; it could be the Americans who are taking action, but even more Australian funds working with the company to ensure the armor I repeat, is the company's priority right now and these conditions on the market. however, all fatality returns particularly positive on the eve of the expiry of the freezing of options to managers. Monday the market will re-open (maybe even not) in the legitimate return time for the conversion of options. this seasoned with the powerful variable that the Treagus can convince at any time sophisticated institutional investors to invest in the long term on Neuren and to do this must put on the plate something particularly powerful that is 2591. the company has money in cash and zero debts with very advanced and placed trofinetide, a very fragrant vaucher and a 2591 that was already to be presented to the FDA for phase 1 a few years ago.
the reality of the facts is coming slowly out to the detriment of market fraud.